Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer.
10.3857/roj.2013.31.4.185
- Author:
In Bong HA
1
;
Bae Kwon JEONG
;
Hojin JEONG
;
Hoon Sik CHOI
;
Gyu Young CHAI
;
Myoung Hee KANG
;
Hoon Gu KIM
;
Gyeong Won LEE
;
Jae Beom NA
;
Ki Mun KANG
Author Information
1. Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea. jsk92@gnu.ac.kr
- Publication Type:Original Article
- Keywords:
Small cell lung carcinoma;
Radiotherapy;
Chemotherapy
- MeSH:
Anemia;
Chemoradiotherapy*;
Cisplatin;
Consolidation Chemotherapy;
Disease-Free Survival;
Drug Therapy;
Esophagitis;
Etoposide;
Follow-Up Studies;
Humans;
Leukopenia;
Neoplasm Metastasis;
Radiation Pneumonitis;
Radiotherapy;
Recurrence;
Retrospective Studies;
Small Cell Lung Carcinoma*;
Thrombocytopenia
- From:Radiation Oncology Journal
2013;31(4):185-190
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We evaluated the effect of early chemoradiotherapy on the treatment of patients with limited stage small cell lung cancer (LS-SCLC). MATERIALS AND METHODS: Between January 2006 and December 2011, thirty-one patients with histologically proven LS-SCLC who were treated with two cycles of chemotherapy followed by concurrent chemoradiotherapy and consolidation chemotherapy were retrospectively analyzed. The chemotherapy regimen was composed of etoposide and cisplatin. Thoracic radiotherapy consisted of 50 to 60 Gy (median, 54 Gy) given in 5 to 6.5 weeks. RESULTS: The follow-up period ranged from 5 to 53 months (median, 22 months). After chemoradiotherapy, 35.5% of the patients (11 patients) showed complete response, 61.3% (19 patients) showed partial response, 3.2% (one patient) showed progressive disease, resulting in an overall response rate of 96.8% (30 patients). The 1-, 2-, and 3-year overall survival (OS) rates were 66.5%, 41.0%, and 28.1%, respectively, with a median OS of 21.3 months. The 1-, 2-, and 3-year progression free survival (PFS) rates were 49.8%, 22.8%, and 13.7%, respectively, with median PFS of 12 months. The patterns of failure were: locoregional recurrences in 29.0% (nine patients), distant metastasis in 9.7% (three patients), and both locoregional and distant metastasis in 9.7% (three patients). Grade 3 or 4 toxicities of leukopenia, anemia, and thrombocytopenia were observed in 32.2%, 29.0%, and 25.8%, respectively. Grade 3 radiation esophagitis and radiation pneumonitis were shown in 12.9% and 6.4%, respectively. CONCLUSION: We conclude that early chemoradiotherapy for LS-SCLC provides feasible and acceptable local control and safety.
